Open AccessEnoxaparin-induced hepatotoxicity: clinical cases and literature review
Author(s) -
Ю. Н. Кровко,
А. В. Шмигельский,
А. Д. Ахмедов,
А. А. Шульгина,
В А Лукшин,
Д. Ю. Усачёв
Publication year - 2021
Publication title -
vestnik anesteziologii i reanimatologii
Language(s) - English
Resource type - Journals
eISSN - 2541-8653
pISSN - 2078-5658
DOI - 10.21292/2078-5658-2021-18-1-84-92
Subject(s) - medicine , discontinuation , thrombosis , deep vein , adverse effect , warfarin , low molecular weight heparin , surgery , portal vein thrombosis , transaminase , anesthesia , atrial fibrillation , biochemistry , chemistry , enzyme
Low molecular weight heparins, in particular enoxaparin, have a wide range of applications, including prevention and treatment of deep vein thrombosis. The most common adverse effects of these drugs are bleeding and thrombocytopenia, but a clinician should be aware of another less common but not less important adverse effect such as an elevated transaminase level. In 2019, we observed two cases of enoxaparin-induced hepatotoxicity. In the first one, enoxaparin 0.4 ml subcutaneously twice a day was prescribed to a 40-year-old woman as a bridge therapy to discontinue warfarin before elective surgery. In the second case, a 27-year-old man received enoxaparin 0.4 ml subcutaneously twice a day for the prevention of deep vein thrombosis. The elevation of transaminase level for more than 3 times above the norm was noted in both patients which required discontinuation of the drug.